What's in Sinovac Research and Development Co., Ltd.'s pipeline?

Sinovac Research and Development Co., Ltd. has 11 drugs in our index: 6 marketed, 0 filed, 5 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Sinovac Research and Development Co., Ltd.'s portfolio?

Top competitors by shared drug class: Centers for Disease Control and Prevention, Sinovac Biotech Co., Ltd, Sanofi Pasteur, a Sanofi Company, PATH, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sinovac-research-and-development-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sinovac Research and Development Co., Ltd. — Portfolio Competitive Intelligence Brief

Sinovac Research and Development Co., Ltd. pipeline: 6 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 5 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Experimental vaccine 2	Experimental vaccine 2	marketed
Experimental vaccine 3	Experimental vaccine 3	marketed
The SARS-CoV-2 Inactivated Vaccine	The SARS-CoV-2 Inactivated Vaccine	marketed
Experimental vaccine 1	Experimental vaccine 1	marketed
Inactivated COVID-19 Vaccine	Inactivated COVID-19 Vaccine	marketed	inactivated viral vaccine		Immunology
Inactivated SARS-CoV-2 Vaccine (Vero cell）	Inactivated SARS-CoV-2 Vaccine (Vero cell）	marketed	inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens	Immunology / Infectious Disease
control live attenuated mumps vaccine	control live attenuated mumps vaccine	phase 3			Immunology
Sinovac PCV13	Sinovac PCV13	phase 3	vaccine		Immunology
COVID-19 Vaccine,Inactivated	COVID-19 Vaccine,Inactivated	phase 3	Inactivated viral vaccine		Immunology
Investigational live attenuated mumps vaccine	Investigational live attenuated mumps vaccine	phase 3	Live attenuated vaccine		Immunology
Controlled vaccine	Controlled vaccine	phase 3	vaccine		Immunology

Therapeutic area mix

Immunology · 6
Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Centers for Disease Control and Prevention · 4 shared drug classes
Sinovac Biotech Co., Ltd · 4 shared drug classes
Sanofi Pasteur, a Sanofi Company · 4 shared drug classes
PATH · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
Novartis · 3 shared drug classes
Institute of Medical Biology, Chinese Academy of Medical Sciences · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sinovac Research and Development Co., Ltd.:

Cite this brief

Drug Landscape (2026). Sinovac Research and Development Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sinovac-research-and-development-co-ltd. Accessed 2026-05-16.